SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes

Inclusion Criteria: * Men and women ≥18 years old * T2D (according to World Health Organization (WHO) criteria) of less than 4 years duration * BMI 18.5-45 kg/m2 * Drug naïve or oral monotherapy with glucose-lowering drug. * Accepting NDR participation and other register data collection. Exclusion Criteria: * Known or suspected other form of diabetes than type 2 * Ongoing or more than \>4 weeks in total of any previous treatment with: insulin, GLP-1 receptor agonists, SGLT2 inhibitors or combination of any diabetes medications * Medical need to start or intensify any specific GLD treatment, e.g. insulin due to marked hyperglycemia * HbA1c \>70 mmol/mol for patients on monotherapy, \>80 in drug naïve * Contraindication to either metformin or dapagliflozin, or any unacceptable risk with either treatment as assessed by the investigator * History or signs of established cardiovascular disease: diagnosis of myocardial infarction, angina pectoris, heart failure, stroke, lower extremity arterial disease, any limb amputation (except due to trauma or malignancy) * Any serious illness or other condition with short life expectancy (\<4 yr) * Renal impairment (eGFR \<60 ml/min/1,73m2) * Any condition, as judged by the investigator, that suggests that the patient will be non-compliant or otherwise unsuitable to study medication or study participation * Pregnancy or breastfeeding, women of childbearing potential (WOCBP; including perimenopausal women who have had a menstrual period wit…